We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

126 hedge funds and large institutions have $324M invested in Ventyx Biosciences in 2024 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 33 increasing their positions, 39 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more capital invested

Capital invested by funds: $112M → $324M (+$213M)

23.08% more ownership

Funds ownership: 76.5%99.58% (+23%)

19% more call options, than puts

Call options by funds: $1.27M | Put options by funds: $1.07M

16% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 37

4% more funds holding

Funds holding: 121126 (+5)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

15% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 39

Holders
126
Holders Change
+5
Holders Change %
+4.13%
% of All Funds
1.82%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
43
Increased
33
Reduced
39
Closed
37
Calls
$1.27M
Puts
$1.07M
Net Calls
+$205K
Net Calls Change
+$2.73M
Name Holding Trade Value Shares
Change
Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
26
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.62M +$1.12M +244,967 +106%
Millennium Management
27
Millennium Management
New York
$2.6M -$6.68M -1,461,880 -76%
Macquarie Group
28
Macquarie Group
Australia
$2.37M +$1.97M +430,000 New
QUSVM
29
Qiming U.S. Ventures Management
Washington
$2.27M -$1.25M -274,145 -40%
Northern Trust
30
Northern Trust
Illinois
$2.18M -$259K -56,638 -12%
Charles Schwab
31
Charles Schwab
California
$2.12M +$282K +61,693 +19%
Fidelity Investments
32
Fidelity Investments
Massachusetts
$2.08M +$1.41M +309,138 +445%
SCM
33
Sio Capital Management
New York
$2.08M +$1.73M +378,000 New
Walleye Capital
34
Walleye Capital
New York
$1.74M +$1.18M +258,483 +450%
Bank of America
35
Bank of America
North Carolina
$1.67M +$1.15M +251,356 +484%
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
$1.08M -$1.46M -318,505 -62%
BC
37
BIT Capital
Germany
$994K +$826K +180,708 New
LIP
38
Lighthouse Investment Partners
Florida
$932K +$775K +169,498 New
EAM
39
Exome Asset Management
New York
$902K +$750K +163,922 New
Bank of New York Mellon
40
Bank of New York Mellon
New York
$801K -$47.1K -10,302 -7%
Invesco
41
Invesco
Georgia
$798K +$552K +120,781 +498%
BFM
42
Boothbay Fund Management
New York
$798K +$663K +145,002 New
N
43
Nuveen
North Carolina
$737K -$250K -54,703 -29%
UOC
44
UBS O'Connor
Illinois
$737K +$613K +134,000 New
Jane Street
45
Jane Street
New York
$669K -$1.56M -340,551 -74%
OAC
46
OMERS Administration Corp
Ontario, Canada
$664K +$552K +120,700 New
PP
47
PDT Partners
New York
$663K +$551K +120,502 New
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$647K -$941K -205,762 -64%
Mariner
49
Mariner
Kansas
$639K -$143K -31,226 -21%
VOYA Investment Management
50
VOYA Investment Management
Georgia
$611K +$422K +92,217 +487%

VTYX Hedge Fund Activity: Q1 2024 in Review

126 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q1 2024, worth a combined $324M — up 191% from $112M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new VTYX positions and 37 closed out — a net gain of 6 holders — while 33 added to existing stakes and 39 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $16.2M. The largest seller was Morgan Stanley, cutting an estimated $11.4M.

  • 126 institutional investors held Ventyx Biosciences (VTYX) as of Q1 2024, up from 121 in Q4 2023.
  • Funds reported $324M of Ventyx Biosciences stock for Q1 2024, up 191% quarter-over-quarter.
  • 43 funds opened new Ventyx Biosciences positions in Q1 2024 and 37 closed out, a net change of +6 holders.
  • The largest Ventyx Biosciences buyer in Q1 2024 was Deerfield Management, an estimated $16.2M added.
  • The largest Ventyx Biosciences seller in Q1 2024 was Morgan Stanley, an estimated $11.4M sold.

Based on aggregated 13F filings for Q1 2024.